Novartis holds annual healthcare entrepreneur competition

NovartisNovartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp (BioCamp). Over the course of three days, students will gain first-hand experience of starting a biotechnology company as well as developing and launching an innovative healthcare product. This year's BioCamp focuses on the Company's innovation efforts in new business approaches to the healthcare industry.

"With the aging population and increases in chronic disease around the world, demand for healthcare will continue to grow, well into the future. This will require innovative solutions as more healthcare systems focus on improving patient outcomes" comments Joseph Jimenez, CEO of Novartis. "As Novartis innovates in healthcare, BioCamp underscores our commitment to creating a unique learning environment for young entrepreneurs. This program enables us to forge ties between the healthcare industry and young talent from top universities. We believe this fosters the fresh thinking required to develop truly differentiated products and services with real-world outcomes."

Some of the Company's leading outcome-based business models include collaborations with payors on pricing arrangements, patient compliance programs as well as online support and education. For example, the Company looks at innovative business models that go beyond traditional philanthropic and commercial efforts to reach patients today and those of future generations. The Novartis Arogya Parivar ("Healthy Family") project is one such social healthcare business model involving a deep-rooted outreach program that trains local health educators and offers medicines in smaller, affordable packaging. Through this program, Novartis has reached 42 million people in 33,000 villages in India.

BioCamp is part of the Novartis commitment to supporting the exchange of ideas and thoughts between young talents in science and business and the Company. Top students will meet with leading scientists and members of top management at Novartis including, among others, Rolf M. Zinkernagel, M.D., a Nobel Laureate and member of the Novartis AG Board of Directors, and Prof. Susan Gasser, Director of the Friedrich Miescher Institute for Biomedical Research.

BioCamp students also interact with Novartis scientists and executives who lead the Company's approach to drug development and learn about new breakthrough medicines to address patients' unmet medical needs. The program is designed to help students understand trends and challenges in the biotechnology and life science sectors as well as gain first-hand experience about starting and running a biotech company. BioCamp has helped forge ties with local communities and build connections to aid future innovative collaborations in research and clinical development.

About BioCamp
First started nine years ago in Taiwan, BioCamp has developed into an international forum for science and business students from around the world to learn, exchange ideas and work together in a highly competitive business environment. Previously hosted in Tokyo, Hong Kong and Cambridge, Massachusetts, today's seminar marks the fourth time International BioCamp is hosted at the state-of-the-art Novartis global headquarters in Basel, Switzerland. Since launching BioCamp in 2004, Novartis has introduced more than 500 top graduate students to the life sciences industry and entrepreneurship.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 131,000 full-time-equivalent associates and operate in more than 140 countries around the world.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...